ARS Pharmaceuticals, Inc. Common Stock SPRY
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:53:09.852Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:52:37.75775586Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T00:53:02.617427+00:00
ARS Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.60 | 216.1% | 36.4% | |||
| 25Δ | 4.02 | 257.0% | 35.9% | |||
| 30Δ | 4.45 | 297.9% | 35.5% | |||
| 35Δ | 4.87 | 338.8% | 35.1% | |||
| 40Δ | 5.19 | 337.6% | 32.6% | |||
| 45Δ | 4.35 | 95.8% | 23.9% | 5.46 | 317.7% | 29.1% |
| 50Δ | 4.17 | 95.1% | 21.6% | 5.73 | 297.8% | 25.7% |
| 55Δ | 3.99 | 94.5% | 19.4% | 6.00 | 277.9% | 22.2% |
| 60Δ | 3.81 | 93.8% | 17.1% | 6.27 | 258.0% | 18.8% |
| 65Δ | 3.62 | 93.1% | 14.8% | 6.54 | 238.1% | 15.3% |
| 70Δ | 3.44 | 92.5% | 12.6% | 6.81 | 218.2% | 11.9% |
| 75Δ | 3.26 | 91.8% | 10.3% | 7.08 | 198.4% | 8.4% |
| 80Δ | 3.08 | 91.1% | 8.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.60
- IV
- 216.1%
- B/E move
- 36.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.02
- IV
- 257.0%
- B/E move
- 35.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.45
- IV
- 297.9%
- B/E move
- 35.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.87
- IV
- 338.8%
- B/E move
- 35.1%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.19
- IV
- 337.6%
- B/E move
- 32.6%
45Δ
- Pseudo strike
- 4.35
- IV
- 95.8%
- B/E move
- 23.9%
- Pseudo strike
- 5.46
- IV
- 317.7%
- B/E move
- 29.1%
50Δ
- Pseudo strike
- 4.17
- IV
- 95.1%
- B/E move
- 21.6%
- Pseudo strike
- 5.73
- IV
- 297.8%
- B/E move
- 25.7%
55Δ
- Pseudo strike
- 3.99
- IV
- 94.5%
- B/E move
- 19.4%
- Pseudo strike
- 6.00
- IV
- 277.9%
- B/E move
- 22.2%
60Δ
- Pseudo strike
- 3.81
- IV
- 93.8%
- B/E move
- 17.1%
- Pseudo strike
- 6.27
- IV
- 258.0%
- B/E move
- 18.8%
65Δ
- Pseudo strike
- 3.62
- IV
- 93.1%
- B/E move
- 14.8%
- Pseudo strike
- 6.54
- IV
- 238.1%
- B/E move
- 15.3%
70Δ
- Pseudo strike
- 3.44
- IV
- 92.5%
- B/E move
- 12.6%
- Pseudo strike
- 6.81
- IV
- 218.2%
- B/E move
- 11.9%
75Δ
- Pseudo strike
- 3.26
- IV
- 91.8%
- B/E move
- 10.3%
- Pseudo strike
- 7.08
- IV
- 198.4%
- B/E move
- 8.4%
80Δ
- Pseudo strike
- 3.08
- IV
- 91.1%
- B/E move
- 8.0%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 195.02% |
Biotechnology
SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic…
More →SRRK
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which…
More →SRZN
Description unavailable
More →STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases…
More →STRO
Description unavailable
More →STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is…
More →